Skip to main content
TipRanks
Go Ultimate75% OFF

HeraMED Ltd. (HMD) AI Stock Analysis

4 Followers
AU:HMD

HeraMED Ltd.

(ASX:HMD)

Select Model
Rating:38Underperform
Price Target:AUD 0.04â–²(2.86% Upside)
Action:reiterated
Date:10/29/26

The overall score is severely depressed, driven primarily by the company's deteriorating financial performance, including a collapse in gross margin and persistent losses. Technical trends confirm sustained bearish momentum with the stock trading below all major moving averages. The negative P/E ratio and lack of dividend yield further diminish any investment case, leaving the stock in a highly speculative and high-risk position.

Positive Factors
Improved Gross MarginThe move from negative gross margins in 2020–2022 to roughly 60% in 2023–2024 shows that HeraMED’s offerings can generate positive gross profit. If maintained, this improvement provides a stronger base for covering operating costs and converting revenue growth into better earnings over time.
Negative Factors
Revenue ContractionRecent revenue contraction and historical volatility indicate that commercial expansion has not yet become dependable. A shrinking or inconsistent top line limits operating leverage, makes fixed costs harder to absorb, and reduces the company’s ability to fund product development and scale from internally generated growth.

HeraMED Ltd. (HMD) vs. iShares MSCI Australia ETF (EWA)

-30%-20%-10%0%10%20%30%AU:HMD-12.50%EWA+8.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 40.55M
Dividend Yield
―
Average Volume (3M)
756.33K
Price to Earnings (P/E)
-10.6
Beta (1Y)
1.17
Revenue Growth
-52.35%
EPS Growth
40.38%
Country
Australia
Employees
6
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

HeraMED Ltd. Business Overview & Revenue Model

Company Description

HeraMED Limited and its associated entities are dedicated to the design, production, and sale of at-home fetal heart rate monitors and comprehensive pregnancy monitoring systems. These solutions are offered to consumers throughout Australia, Europe,...

HeraMED Ltd. Financial Statement Overview

Summary

Financial health is critically weak. Revenue is declining sharply, gross margin has collapsed to 0%, and the company remains deeply unprofitable with negative cash flows. The only mitigating factor is a debt-free balance sheet, but the low equity base offers minimal cushion against ongoing losses.

Income Statement

15Very Negative

Balance Sheet

25Negative

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue102.69K195.77K225.49K413.19K215.81K83.68K
Gross Profit95.42K99.78K135.29K248.12K-214.69K-219.50K
EBITDA-2.21M-2.56M-3.15M-3.97M-2.83M-3.67M
Net Income-2.36M―-3.40M-4.50M-4.88M-5.71M
Balance Sheet
Total Assets2.15M994.94K2.78M2.01M4.19M4.57M
Cash, Cash Equivalents and Short-Term Investments2.03M914.65K3.13M723.29K2.64M3.55M
Total Debt0282.39K815.96K209.37K179.53K3.41M
Total Liabilities403.51K559.96K1.06M1.55M1.30M4.13M
Stockholders Equity1.75M621.27K1.72M466.70K2.88M-105.66K
Cash Flow
Free Cash Flow-2.18M-2.44M-2.98M-5.57M-3.20M-3.20M
Operating Cash Flow-2.18M-2.44M-2.98M-5.57M-2.52M-3.12M
Investing Cash Flow000-2,046-690.78K-85.43K
Financing Cash Flow3.54M1.27M6.88M2.96M2.54M4.88M

HeraMED Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price0.04

Price Trends

50DMA0.04Negative
100DMA0.04Negative
200DMA0.04Negative

Market Momentum

MACD-0.00Positive
RSI45.98Neutral
STOCH33.33Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HMD, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 45.98 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HMD.

HeraMED Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:HMD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:RMDAU:RMD84OutperformAUD 50.09B21.5125.14%0.98%1.54%4.43%
AU:CMPAU:CMP54NeutralAUD 46.94M209.090.93%―18.54%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:AT1AU:AT144NeutralAUD 10.83M-2.86-48.97%―40.65%45.45%
AU:UCMAU:UCM43NeutralAUD 3.12M-1.56-1788.57%―-52.22%44.79%
AU:IPDAU:IPD39UnderperformAUD 18.33M-0.43-259.31%―14.85%-1.74%
AU:HMDAU:HMD38UnderperformAUD 40.55M-10.59-198.77%―-52.35%40.38%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%AU:HMDAU:CMPAU:IPDAU:UCMAU:AT1AU:RMDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:HMD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:HMDHeraMED Ltd.0.04-0.00-5.41%
AU:CMPCompumedics Limited0.23-0.10-28.79%
AU:IPDImpedimed Limited0.01-0.02-60.00%
AU:UCMUscom Limited0.010.000.00%
AU:AT1Atomo Diagnostics Ltd.0.01-0.02-56.67%
AU:RMDResmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh35.44-2.79-7.29%

HeraMED Ltd. Corporate Events

HeraMED Wins People’s Choice Award at Garmin Health Awards

Nov 1, 2026

HeraMED won the People’s Choice Award at the 2026 Garmin Health Awards in Bangkok, selected from six finalists among 113 applications spanning 31 countries. The award recognises its HeraCARE platform and its focus on connected, personalised women’s h...

HeraMED Secures First Major U.S. SaaS Rollout With Lee Health

Oct 30, 2026

HeraMED has advanced its U.S. commercialisation strategy by moving its Digital Pregnancy Journey program with Lee Health from a six-month pilot into a paid, recurring SaaS deployment. The initial US$317,200 contract covers 200 mothers and includes He...

HeraMED Secures Full-Scale Digital Maternity Rollout with US Health System Lee Health

Sep 15, 2026

Lee Health, a major non-profit healthcare system in Southwest Florida that delivers more than 8,000 babies annually, has approved the full commercial deployment of HeraMED’s digital maternity solution after a successful six-month pilot. The program,...

HeraMED Shares Halted Ahead of Material Commercial Deployment News

Sep 14, 2026

HeraMED Ltd. has requested and received a trading halt on its ordinary shares from the ASX, with the suspension effective immediately and expected to last until either the start of normal trading on 17 September 2026 or the release of a pending annou...

HeraMED Issues 3.3 Million Unquoted Performance Rights Under Incentive Plan

Sep 1, 2026

HeraMED Ltd. has notified the market of the issue of 3.3 million unquoted performance rights under its employee incentive scheme, dated 14 August 2026. The new awards, which are not intended to be quoted on the ASX, underscore the company’s use of eq...

HeraMED Narrows Half-Year Loss as Revenue Slumps but Asset Backing Improves

Aug 28, 2026

HeraMED Limited reported a sharp contraction in revenue for the half-year ended 30 June 2026, with income from ordinary activities falling 72.5% to $38,325, while its net loss narrowed 29.2% to $1.6 million compared with the prior corresponding perio...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 29, 2026